Transcatheter Aortic Valve Replacement in Hypertrophic Cardiomyopathy: A Systematic Review and Meta‐Analysis
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.31367 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift Catheterization and Cardiovascular Interventions, 2025. Verfasst von Ashraf Ahmed und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Internal Medicine, Bridgeport Hospital, Yale New Haven Health, Bridgeport, Connecticut, USA. Hauptthemen laut MEDLINE: Cardiomyopathy, Hypertrophic, Transcatheter Aortic Valve Replacement, Aortic Valve Stenosis, Aortic Valve. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: The authors received no specific funding for this work..
Abstract (Originalsprache)
Background
The co‐existence of severe aortic stenosis (AS) and hypertrophic cardiomyopathy (HCM) is not uncommon. Surgical intervention is the gold standard management. Patients with high surgical risk might undergo transcatheter aortic valve replacement (TAVR). However, TAVR outcomes are unclear in this population. We aimed to investigate the impact of HCM on the outcomes of TAVR.
Aim
We aim to investigate the outcomes of TAVR in patients with HCM.
Methods
We systematically searched PubMed, EMBASE, and Scopus for studies that compared outcomes of TAVR procedure between patients with HCM and those without it. Using the random‐effects model, the odds ratios (OR) with 95% confidence interval (CI) were reported.
Results
We screened 102 articles and identified three observational cohort studies. Compared to patients who underwent TAVR without underlying HCM, TAVR for AS co‐existed with HCM was associated with higher rates of mortality (OR 5.79; 95% CI: 3.38; 9.91, p < 0.0001), cardiogenic shock (OR 4.55; 95% CI: 3.40; 6.08, p < 0.0001), aortic dissection (OR 4.95; 95% CI: 3.17; 7.74, p < 0.0001), vascular complications (OR 2.10; 95% CI: 1.27; 3.47, p = 0.004), and renal impairment (OR 1.80; 95% CI: 1.36; 2.40, p < 0.0001). There was no difference between the comparison groups in terms of complete heart block, new permanent pacemaker implantation, or bleeding.
Conclusion
In patients with severe AS and HCM, TAVR was associated with significantly higher occurrence of mortality, cardiogenic shock, aortic dissection, vascular complications, and renal impairment as well as the need for mechanical ventilation than patients who did not have HCM.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Internal Medicine, Bridgeport Hospital, Yale New Haven Health, Bridgeport, Connecticut, USA.
- Department of Pharmacy, Heart Hospital, Hamad Medical Corporation, Doha, Qatar.
- Division of Cardiovascular Diseases, Bridgeport Hospital, Yale New Haven Health, Bridgeport, Connecticut, USA.
ORCID-Profile: Ashraf Ahmed, Rasha Kaddoura
Förderung
- The authors received no specific funding for this work.
Zitieren
APA
Ahmed, A., Kaddoura, R., Aggarwal, A., Zinyandu, T., Webber, F., Davila, C., & Zarich, S. (2025). Transcatheter Aortic Valve Replacement in Hypertrophic Cardiomyopathy: A Systematic Review and Meta‐Analysis. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.31367
Vancouver
Ahmed A, Kaddoura R, Aggarwal A, Zinyandu T, Webber F, Davila C, et al. Transcatheter Aortic Valve Replacement in Hypertrophic Cardiomyopathy: A Systematic Review and Meta‐Analysis. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.31367
BibTeX
@article{Ahmed2025,
author = {Ahmed, Ashraf and Kaddoura, Rasha and Aggarwal, Abhinav and Zinyandu, Tawanda and Webber, Fabricio and Davila, Carlos and Zarich, Stuart},
title = {Transcatheter Aortic Valve Replacement in Hypertrophic Cardiomyopathy: A Systematic Review and Meta‐Analysis},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.31367}
}
EUVIMED